Where does CytoVale Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), CytoVale Inc. ranks #31,349 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does CytoVale Inc. hold?

CytoVale Inc. holds 8 US utility patents granted between 2019 and 2024, spanning 8 technology areas.

What is CytoVale Inc.'s Innovation Score?

CytoVale Inc. has an Innovation Score of 45.8 out of 100 (top 22% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does CytoVale Inc. focus on?

CytoVale Inc.'s top technology area is B01L (Chemical OR Physical Laboratory Apparatus FOR General USE) with 8 patents, ranking #237 of 1,325 assignees active in that subclass. Grants appear in 8 CPC subclasses total.

Is CytoVale Inc.'s patent grant rate increasing or decreasing?

CytoVale Inc.'s recent grant velocity is +600% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for CytoVale Inc.'s patents?

CytoVale Inc.'s patents average 13.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the CytoVale Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

CytoVale Inc.

USPTO PatentsView assignee record - 8 granted patents across 8 technology areas, recorded in grant years 2019–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: B01L (Chemical OR Physical Laboratory Apparatus FOR General USE).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Cytovale ranks #31,349 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 8 technology areas.

#31,349
of 49,997 US assignees by volume: Top 22%
by Innovation Score (45.8/100): 13.8
avg claims per patent: +600%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R31349 · US Corporation #31,349 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 8 grants
MID-PACK #31,349/49,997
PHOTO-FINISH Cypris Medical
CPC-NARROW B01L · 8 areas
INNOV-PAR 45.8/100
CLAIMS-RICH 13.8 claims/avg
TYPE-USCORP US Corporation
VEL-SURGE +600% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Cypris Medical, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Cytovale’s 45.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 7.6 pts (17%) Velocity 20.0 pts (44%) Breadth 10.0 pts (22%) Claim depth 8.3 pts (18%)

Qualcomm Incorporated · highest

85
CytoVale · this assignee

46
3D Lighting… · lowest

7

What this shows Cytovale's Innovation Score is 45.8/100 (top 22% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Cytovale?

Each dot is one of Cytovale’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Cytovale’s own 13.8 claims/patent is at or below the 16.1 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Cytovale vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Cytovale's grants concentrate

CytoVale Inc. is a focused PatentsView assignee: 8 CPC subclasses with 100% of grants classified under B01L (Chemical OR Physical Laboratory Apparatus FOR General USE). Peak complete grant year is 2024 (4 grants) versus a trough of 1 in 2019. By volume, Cytovale sits between Cypris Medical, Inc. and D. LA Porte SÖHNE GMBH.

Cytovale's three-year grant acceleration

CytoVale Inc. shows 6 grants in 2022–2024 against only 2 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Cypris Medical

8
Cyrano Therapeuti…

8
Cyteir Therapeuti…

8
Cytlimic

8
Cytoveris

8
D Three Enterpris…

8
D&R Tech

8
D LA Porte SÖHNE

8
Cytovale ◀

8

What this shows CytoVale holds 8 patents at rank #31,349, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near CytoVale

By rank, the assignees closest to #31,349 in granted patent volume.

Leaders in B01L (Chemical OR Physical Laboratory Apparatus FOR General USE)

Other assignees with the most granted patents in CytoVale's primary technology class.

Cytovale's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

46 Top 22% higher than 78% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table

CytoVale Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2019	1	12.5%
2021	1	12.5%
2023	2	25.0%
2024	4	50.0%

Which technologies does CytoVale Inc. patent most?

B01L - Chemical OR Physical Laboratory Apparatus FOR General USE 8

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 8

G06T - Image Data Processing OR Generation, IN General 4

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 3

C12M - Apparatus FOR Enzymology OR MICROBIOLOGY; Apparatus FOR Culturing Microorganisms FOR Producing Biomass, FOR Growing Cells OR FOR Obtaining Fermentation OR Metabolic Products, i.e. Bioreactors OR Fermenters 2

G06N - Computing Arrangements Based ON Specific Computational Models 2

G06V - Image OR Video Recognition OR Understanding 2

G16B - Bioinformatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR Genetic OR Protein-related Data Processing IN Computational Molecular Biology 1

Top 8 of 8 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

CytoVale Inc.'s patent record in context - here's where to go next.

CytoVale Inc.'s lead technology class is B01L (Chemical OR Physical Laboratory Apparatus FOR General USE), 100% of its portfolio - see every assignee active in that class. Explore B01L
Ranked #31,349 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare CytoVale Inc. against Cypris Medical, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 45.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.